A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development Journal Article


Authors: Zhao, B.; Oxnard, G. R.; Moskowitz, C. S.; Kris, M. G.; Pao, W.; Guo, P.; Rusch, V.; Ladanyi, M.; Rizvi, N. A.; Schwartz, L. H.
Article Title: A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development
Abstract: Purpose: Tissue biomarker discovery is potentially limited by conventional tumor measurement techniques, which have an uncertain ability to accurately distinguish sensitive and resistant tumors. Semi-automated volumetric measurement of computed tomography imaging has the potential to more accurately capture tumor growth dynamics, allowing for more exact separation of sensitive and resistant tumors and a more accurate comparison of tissue characteristics. Experimental Design: Forty-eight patients with early stage non-small cell lung cancer and clinical characteristics of sensitivity to gefitinib were studied. High-resolution computed tomography was done at baseline and after 3 weeks of gefitinib. Tumors were then resected and molecularly profiled. Unidimensional and volumetric measurements were done using a semiautomated algorithm. Measurement changes were evaluated for their ability to differentiate tumors with and without sensitizing mutations. Results: Forty-four percent of tumors had epidermal growth factor receptor-sensitizing mutations. Receiver operating characteristic curve analysis showed that volumetric measurement had a higher area under the curve than unidimensional measurement for identifying tumors harboring sensitizing mutations (P = 0.009). Tumor volume decrease of >24.9% was the imaging criteria best able to classify tumors with and without sensitizing mutations (sensitivity, 90%; specificity, 89%). Conclusions: Volumetric tumor measurement was better than unidimensional tumor measurement at distinguishing tumors based on presence or absence of a sensitizing mutation. Use of volume-based response assessment for the development of tissue biomarkers could reduce contamination between sensitive and resistant tumor populations, improving our ability to identify meaningful predictors of sensitivity. ©2010 AACR.
Keywords: clinical article; human tissue; cancer surgery; human cell; antineoplastic agents; sensitivity and specificity; tumor volume; lung non small cell cancer; carcinoma, non-small-cell lung; lung neoplasms; epidermal growth factor receptor; tumor markers, biological; tomography, x-ray computed; drug resistance, neoplasm; diagnostic imaging; tumor marker; pilot projects; tumor burden; disease progression; imaging, three-dimensional; gefitinib; tumor growth; quinazolines; tumor resistance; high resolution computer tomography; biomarkers, pharmacological
Journal Title: Clinical Cancer Research
Volume: 16
Issue: 18
ISSN: 1078-0432
Publisher: American Association for Cancer Research  
Date Published: 2010-09-15
Start Page: 4647
End Page: 4653
Language: English
DOI: 10.1158/1078-0432.ccr-10-0125
PUBMED: 20534736
PROVIDER: scopus
PMCID: PMC2940965
DOI/URL:
Notes: --- - "Cited By (since 1996): 1" - "Export Date: 20 April 2011" - "CODEN: CCREF" - "Source: Scopus"
Altmetric Score
MSK Authors
  1. Valerie W Rusch
    652 Rusch
  2. Lawrence H Schwartz
    281 Schwartz
  3. William Pao
    141 Pao
  4. Pingzhen Guo
    10 Guo
  5. Binsheng Zhao
    46 Zhao
  6. Naiyer A Rizvi
    156 Rizvi
  7. Chaya S. Moskowitz
    172 Moskowitz
  8. Marc Ladanyi
    863 Ladanyi
  9. Geoffrey R Oxnard
    24 Oxnard
  10. Mark Kris
    597 Kris